NovaPulse Overview
NovaPulse is a bioconvergence company specializing in the multibillion-dollar peripheral artery disease market. The company is focused on helping the millions of claudication patients who suffer from pain and have trouble walking because of insufficient blood supply to their legs. NovaPulse is the brainchild of the MEDX Xelerator incubator.
Latest News
growth-positive
Almeda Ventures Joins MEDX Xelerator and Israel Innovation Authority in Vascular Medtech Startup NovaPulse Investment
MEDX Xelerator has founded NovaPulse Ltd., a bio-convergence company addressing the peripheral artery disease (PAD) market. Almeda Ventures has become a seed investor in NovaPulse. The initiative aims to develop a treatment for claudication patients suffering from pain and difficulty walking due to insufficient blood supply in their legs. NovaPulse was formed with strategic input from Boston Scientific and support from the Israeli Innovation Authority. The venture creation process of MEDX Xelerator has been successful in driving quality deal flow for the incubator. Almeda Ventures sees the collaboration as an opportunity to build solutions for real clinical and commercial unmet needs. NovaPulse aims to improve the standard of care and quality of life for patients with peripheral arterial disease.
Investment
growth-positive
אלמדה ונצ'רס מוסיפה השקעה נוספת לפורטפוליו שלה
אלמדה ונצרס מודיעה על השקעה בחברת פורטפוליו חדשה, עשירית במספר, בה תשקיע במסגרת יוזמה חדשה של חממת מדקס (MEDX) – חברת NovaPulse, שהינה חברת ביו-קונברגנס. NovaPulse מתמקדת בשוק החולים במחלת העורקים ההיקפיים (PAD) ומפתחת פיתרון לחולי קלאודיקציה. ההשקעה מציינת צעד חיובי לחברת אלמדה ונצרס בתחום הביו-קונברגנס.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 1 |
| Investors | 2 |
Team Members
1
Employees: 1-10
Web & Social Links
Locations
Ariel Sharon Blvd 8, Or Yehuda, Israel
Photos & Videos
No files yet
